©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 7, 2024; 30(17): 2294-2297
Published online May 7, 2024. doi: 10.3748/wjg.v30.i17.2294
Published online May 7, 2024. doi: 10.3748/wjg.v30.i17.2294
Expanding indications for chronic hepatitis B treatment: Is it really desirable to treat everyone?
Fabiola Di Dato, Raffaele Iorio, Department of Translational Medical Science, Section of Pediatrics, University of Naples Federico II, Naples 80131, Italy
Author contributions: Di Dato F and Iorio R wrote the first draft and reviewed and finalized the editorial.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Raffaele Iorio, MD, Associate Professor, Department of Translational Medical Science, Section of Pediatrics, University of Naples Federico II, Via Pansini 5, Naples 80131, Italy. riorio@unina.it
Received: February 6, 2024
Revised: March 8, 2024
Accepted: April 15, 2024
Published online: May 7, 2024
Processing time: 89 Days and 2.2 Hours
Revised: March 8, 2024
Accepted: April 15, 2024
Published online: May 7, 2024
Processing time: 89 Days and 2.2 Hours
Core Tip
Core Tip: There is a growing trend to expand the indications for the treatment of chronic hepatitis B. Starting from the concept that current therapies for chronic hepatitis B are unable to completely eradicate hepatitis B virus infection, this editorial critically analyzes the long-term efficacy of the available therapies and the rationale for an extension of current indications.